209 related articles for article (PubMed ID: 26215085)
1. Pharmacokinetic digital phantoms for accuracy assessment of image-based dosimetry in (177)Lu-DOTATATE peptide receptor radionuclide therapy.
Brolin G; Gustafsson J; Ljungberg M; Gleisner KS
Phys Med Biol; 2015 Aug; 60(15):6131-49. PubMed ID: 26215085
[TBL] [Abstract][Full Text] [Related]
2. Fast voxel-level dosimetry for (177)Lu labelled peptide treatments.
Hippeläinen E; Tenhunen M; Sohlberg A
Phys Med Biol; 2015 Sep; 60(17):6685-700. PubMed ID: 26270032
[TBL] [Abstract][Full Text] [Related]
3. Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [
Mansouri Z; Salimi Y; Akhavanallaf A; Shiri I; Teixeira EPA; Hou X; Beauregard JM; Rahmim A; Zaidi H
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1516-1529. PubMed ID: 38267686
[TBL] [Abstract][Full Text] [Related]
4. Uncertainty propagation for SPECT/CT-based renal dosimetry in (177)Lu peptide receptor radionuclide therapy.
Gustafsson J; Brolin G; Cox M; Ljungberg M; Johansson L; Gleisner KS
Phys Med Biol; 2015 Nov; 60(21):8329-46. PubMed ID: 26458139
[TBL] [Abstract][Full Text] [Related]
5. Personalized dosimetry of
Carter LM; Ocampo Ramos JC; Kesner AL
Biomed Phys Eng Express; 2021 Aug; 7(5):. PubMed ID: 34271565
[No Abstract] [Full Text] [Related]
6. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
7. A dosimetry procedure for organs-at-risk in
Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging.
Gleisner KS; Brolin G; Sundlöv A; Mjekiqi E; Östlund K; Tennvall J; Larsson E
J Nucl Med; 2015 Jul; 56(7):976-84. PubMed ID: 25999429
[TBL] [Abstract][Full Text] [Related]
9. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
10. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
11. Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios.
Kupitz D; Wetz C; Wissel H; Wedel F; Apostolova I; Wallbaum T; Ricke J; Amthauer H; Grosser OS
PLoS One; 2017; 12(11):e0187570. PubMed ID: 29107992
[TBL] [Abstract][Full Text] [Related]
12. Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment.
Svensson J; Berg G; Wängberg B; Larsson M; Forssell-Aronsson E; Bernhardt P
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):947-55. PubMed ID: 25655484
[TBL] [Abstract][Full Text] [Related]
13. Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in
Hagmarker L; Svensson J; Rydén T; Gjertsson P; Bernhardt P
Cancer Biother Radiopharm; 2017 Nov; 32(9):335-343. PubMed ID: 29125780
[TBL] [Abstract][Full Text] [Related]
14. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.
Hardiansyah D; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Phys Med; 2017 Oct; 42():298-304. PubMed ID: 28739143
[TBL] [Abstract][Full Text] [Related]
15. Twins in spirit part IV - [
Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
[TBL] [Abstract][Full Text] [Related]
16. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
Garkavij M; Nickel M; Sjögreen-Gleisner K; Ljungberg M; Ohlsson T; Wingårdh K; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1084-92. PubMed ID: 20127957
[TBL] [Abstract][Full Text] [Related]
17. Effect of image registration on 3D absorbed dose calculations in
Grassi E; Fioroni F; Berenato S; Patterson N; Ferri V; Braglia L; Filice A; Versari A; Iori M; Spezi E
Phys Med; 2018 Jan; 45():177-185. PubMed ID: 29472084
[TBL] [Abstract][Full Text] [Related]
18. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During
Hagmarker L; Svensson J; Rydén T; van Essen M; Sundlöv A; Gleisner KS; Gjertsson P; Bernhardt P
J Nucl Med; 2019 Oct; 60(10):1406-1413. PubMed ID: 30902877
[TBL] [Abstract][Full Text] [Related]
19. The importance of BMI in dosimetry of
Fallahpoor M; Abbasi M; Asghar Parach A; Kalantari F
Appl Radiat Isot; 2017 Jun; 124():1-6. PubMed ID: 28284122
[TBL] [Abstract][Full Text] [Related]
20. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
